## TABLE OF CONTENTS

**Volume One**

### How to Use The Service

### Newsletters

**Tab 100: Overview of FDA Enforcement**

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive Summary</td>
<td>¶100</td>
</tr>
<tr>
<td>FDA’s Enforcement Universe</td>
<td>¶101</td>
</tr>
<tr>
<td>FDA’s Enforcement Objective</td>
<td>¶102</td>
</tr>
<tr>
<td>Appropriate Response to FDA Enforcement</td>
<td>¶103</td>
</tr>
<tr>
<td><strong>Administrative Enforcement Powers</strong></td>
<td>¶110</td>
</tr>
<tr>
<td>Civil Enforcement Litigation</td>
<td>¶121</td>
</tr>
<tr>
<td>Criminal Enforcement Litigation</td>
<td>¶122</td>
</tr>
<tr>
<td>Relationship Between Criminal and Civil/ Administrative Sanctions</td>
<td>¶123</td>
</tr>
<tr>
<td>Relationship Between FDA Enforcement</td>
<td>¶124</td>
</tr>
<tr>
<td><strong>FDA’s Enforcement Policy</strong></td>
<td>¶130</td>
</tr>
<tr>
<td>Prior Notice</td>
<td>¶131</td>
</tr>
<tr>
<td><strong>Why FDA Decides to Pursue Enforcement</strong></td>
<td>¶140</td>
</tr>
<tr>
<td>Recent Enforcement Trends</td>
<td>¶141</td>
</tr>
<tr>
<td><strong>FDA Regulation of Products in Interstate Commerce</strong></td>
<td>¶150</td>
</tr>
<tr>
<td><strong>How FDA Rulemaking Affects Law Enforcement</strong></td>
<td>¶160</td>
</tr>
<tr>
<td>FDA’s Use of Unofficial Regulations</td>
<td>¶161</td>
</tr>
<tr>
<td>How Courts Interpret FDA Rulemaking</td>
<td>¶162</td>
</tr>
<tr>
<td>FDA and Public Participation</td>
<td>¶163</td>
</tr>
<tr>
<td><strong>FDA and Other Federal Agencies</strong></td>
<td>¶170</td>
</tr>
<tr>
<td>FDA and Congress</td>
<td>¶171</td>
</tr>
<tr>
<td><strong>FDA and State and Local Agencies</strong></td>
<td>¶180</td>
</tr>
<tr>
<td>State Embargoes</td>
<td>¶181</td>
</tr>
<tr>
<td>FDA Cooperation with States</td>
<td>¶182</td>
</tr>
<tr>
<td>Preemption</td>
<td>¶183</td>
</tr>
<tr>
<td>FDA and Bioterrorism</td>
<td>¶184</td>
</tr>
<tr>
<td>State Enforcement of Tobacco Product Restrictions</td>
<td>¶185</td>
</tr>
<tr>
<td><strong>FDA and International Collaboration</strong></td>
<td>¶190</td>
</tr>
<tr>
<td>FDA’s MRA With the European Union</td>
<td>¶191</td>
</tr>
</tbody>
</table>

**Tab 200: FDA’s Enforcement Organization: Who Does What**

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive Summary</td>
<td>¶200</td>
</tr>
<tr>
<td>FDA as Part of Executive Branch of Government</td>
<td>¶210</td>
</tr>
<tr>
<td>FDA Field Offices: Their Operations and Role in Enforcement</td>
<td>¶220</td>
</tr>
<tr>
<td>Regional Offices</td>
<td>¶221</td>
</tr>
<tr>
<td>District Offices</td>
<td>¶222</td>
</tr>
<tr>
<td>Resident Posts</td>
<td>¶223</td>
</tr>
<tr>
<td>Inspections Branch</td>
<td>¶224</td>
</tr>
<tr>
<td>Laboratory Branch</td>
<td>¶225</td>
</tr>
<tr>
<td>Compliance Branch</td>
<td>¶226</td>
</tr>
<tr>
<td>FDA Office Locations and Information</td>
<td>¶227</td>
</tr>
<tr>
<td>International Offices and Posts</td>
<td>¶228</td>
</tr>
<tr>
<td><strong>FDA Centers: Their Operations and Role in Enforcement</strong></td>
<td>¶230</td>
</tr>
<tr>
<td>Center for Drug Evaluation and Research (CDER)</td>
<td>¶231</td>
</tr>
<tr>
<td>Center for Devices and Radiological Health (CDRH)</td>
<td>¶232</td>
</tr>
<tr>
<td>Center for Food Safety and Applied Nutrition (CFSAN)</td>
<td>¶233</td>
</tr>
<tr>
<td>Center for Biologics Evaluation and Research (CBER)</td>
<td>¶234</td>
</tr>
<tr>
<td>Center for Veterinary Medicine (CVM)</td>
<td>¶235</td>
</tr>
<tr>
<td>Center for Tobacco Products (CTP)</td>
<td>¶236</td>
</tr>
<tr>
<td><strong>FDA’s Office of Regulatory Affairs: Supervising Enforcement</strong></td>
<td>¶240</td>
</tr>
<tr>
<td>Office of Enforcement and Import Operations</td>
<td>¶241</td>
</tr>
<tr>
<td>Other Operational Offices</td>
<td>¶242</td>
</tr>
<tr>
<td>Office of Criminal Investigations</td>
<td>¶243</td>
</tr>
<tr>
<td><strong>Office of the Commissioner</strong></td>
<td>¶250</td>
</tr>
<tr>
<td><strong>Office of the Chief Counsel</strong></td>
<td>¶260</td>
</tr>
<tr>
<td>U.S. Department of Justice</td>
<td>¶270</td>
</tr>
<tr>
<td>U.S. Attorney’s Office</td>
<td>¶271</td>
</tr>
<tr>
<td>Office of Consumer Protection Litigation, Civil Division</td>
<td>¶272</td>
</tr>
<tr>
<td><strong>Sources of Information About FDA Enforcement</strong></td>
<td>¶280</td>
</tr>
<tr>
<td>FDA Manuals and Other Materials</td>
<td>¶281</td>
</tr>
<tr>
<td>Freedom of Information Act (FOIA)</td>
<td>¶282</td>
</tr>
<tr>
<td>Trade Press and Other Information Sources</td>
<td>¶283</td>
</tr>
<tr>
<td>FDA Internet Sites</td>
<td>¶284</td>
</tr>
<tr>
<td>Sources of Additional Information</td>
<td>¶285</td>
</tr>
<tr>
<td><strong>Dispute Resolution</strong></td>
<td>¶290</td>
</tr>
</tbody>
</table>

**Tab 300: Inspections**

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive Summary</td>
<td>¶300</td>
</tr>
<tr>
<td>FDA Annual Inspection Statistics</td>
<td>¶301</td>
</tr>
<tr>
<td>General Characteristics of FDA Inspections</td>
<td>¶302</td>
</tr>
<tr>
<td><strong>FDA’s Authorities During Inspections</strong></td>
<td>¶310</td>
</tr>
<tr>
<td>FDA’s Authority To Obtain Product Records</td>
<td>¶311</td>
</tr>
<tr>
<td>FDA’s Authority To Inspect Carriers</td>
<td>¶312</td>
</tr>
<tr>
<td>Inspections Without Warrants</td>
<td>¶313</td>
</tr>
<tr>
<td>Consent</td>
<td>¶314</td>
</tr>
<tr>
<td><strong>FDA’s Reasons for Inspecting Companies</strong></td>
<td>¶320</td>
</tr>
<tr>
<td>Company Circumstances That Trigger</td>
<td>¶321</td>
</tr>
<tr>
<td>FDA’s Expert Investigators</td>
<td>¶322</td>
</tr>
<tr>
<td><strong>The FDA Inspection</strong></td>
<td>¶330</td>
</tr>
<tr>
<td>How Investigators Prepare for Inspections</td>
<td>¶331</td>
</tr>
<tr>
<td>Investigators’ Credentials and Notices of Inspection</td>
<td>¶332</td>
</tr>
<tr>
<td>Entry and Observation</td>
<td>¶333</td>
</tr>
<tr>
<td>Investigators’ Access to Documents</td>
<td>¶334</td>
</tr>
</tbody>
</table>
Tab 600: Recalls and Administrative Injunction

Executive Summary ...........................................................................¶600
Voluntary vs. Mandatory Recalls ..................................................¶601
Company Recall Plans .................................................................¶602

Definition of a Recall .....................................................................¶610
Market Withdrawals and Stock Recoveries ....................................¶611
Notifying the FDA .................................................................¶612
Information Required by the FDA ..................................................¶613
Classification Criteria for Recalls ..................................................¶614
FDA Guidelines for Recalls .........................................................¶615
Reporting Corrections and Removals .............................................¶616

Company-initiated Recalls ............................................................¶620
FDA-requested Recalls ..................................................................¶630

Recall Strategy .............................................................................¶640
Depth of Recall ..............................................................................¶641
Public Warning ...............................................................................¶642
Effectiveness Checks .....................................................................¶643
FDA Requirements for Company Communications ......................¶644
Implementing a Recall Plan .........................................................¶645

Consequences of a Recall .............................................................¶650
Need to Protect Information .........................................................¶651
Need to Prepare for Inspection .......................................................¶652

FDA-ordered Recalls .....................................................................¶660
Medical Devices .............................................................................¶661
Infant Formula .............................................................................¶662
Biological Products ....................................................................¶663
Foods .........................................................................................¶664
Tobacco Products ........................................................................¶665

Tab 700: Product Approvals

Executive Summary ...........................................................................¶700
Suspensions and Withdrawals .......................................................¶701
Deferral, Delay and Denial of Approval ...........................................¶702
The “Debarment” Law ....................................................................¶703

Approvals Subject to Suspension ...................................................¶710
New Human or Animal Drugs ........................................................¶711
Biological Products ........................................................................¶712
Low-acid Canned Foods ................................................................¶713
Medical Devices ............................................................................¶714

Withdrawal of Product Approvals ...................................................¶720
Grounds for Withdrawal ................................................................¶721
Inspection Evidence .......................................................................¶722
Process for Withdrawal of Product License .....................................¶723
Summary Judgement for Withdrawing Approvals .........................¶724
Withdrawal of ANDA Approvals ....................................................¶725
Exports .........................................................................................¶726

When FDA Finds Fraud in Product

Applications ......................................................................................¶730
Temporary Denial of ANDA Approvals ............................................¶731
Temporary Suspension of Distribution of Generic Human Drugs ....¶732
The Application Integrity Policy .......................................................¶733
Application Integrity Policy and Corrective Action .........................¶734
Validity Assessment Under the Application Integrity Policy ............¶735
Table 700 (cont’d)
Application Integrity Policy Decisions Are Not Final .............................................. ¶736
Relationship Between the Application Integrity Policy and the “Debarment” Law .......... ¶737
Fraud in Approved Applications ......................................................... ¶738
AIIP List ................................................................................. ¶739
Debarment ............................................................................. ¶740
What Debarment Means ....................................................................... ¶741
Debarment of Companies ........................................................................ ¶742
Debarment of Individuals ........................................................................ ¶743
Implementation of Debarment Authority ................................................. ¶744
Debarment Status Chart ........................................................................... ¶745
Additional Actions Affecting Product Approvals ................................................. ¶750
FDA Refusal To File ............................................................................ ¶751
Preapproval Inspections ........................................................................... ¶752
Compliance Tracking Systems ................................................................. ¶753
Downgrading Therapeutic Equivalence Evaluations of Drugs ......................... ¶754
Tab 800: Government Contracts
Executive Summary ............................................................................... ¶800
FDA’s Government-wide Quality Assurance Program (GWQAP) ......................... ¶810
Procurement Duties ............................................................................... ¶811
Pre-award Evaluation Process ..................................................................... ¶812
Consequences of Unacceptable Determinations ............................................ ¶813
FDA’s Compliance Status Information System (COMSTAT) ............................... ¶814
Criminal Fraud and Debarment in Government Procurement Activities ................. ¶820
Tab 900: Imports
Executive Summary ............................................................................... ¶900
Trends in Import Enforcement ..................................................................... ¶901
Statutory Authority Over Imports ................................................................. ¶910
U.S. Bureau of Customs and Border Protection ................................................ ¶911
FDA’s Operational and Administrative System for Import Support (OASIS) ............ ¶912
FDA’s Predictive Risk-based Evaluation for Dynamic Import Compliance Targeting (PREDICT) System ........................................................................... ¶913
FDA’s Permissive Debarment Authority for Food Importers .................................... ¶914
Import Alerts and Detention ........................................................................ ¶920
Detention ................................................................................................. ¶921
Automatic Detention .................................................................................. ¶922
The Question of Detentions as Rulemakings .................................................... ¶923
Responding to Detention ............................................................................ ¶924
Import Hearings ....................................................................................... ¶925
The Import Process ................................................................................... ¶930
Reconditioning and Relabeling ...................................................................... ¶931
Redelivery Bond ....................................................................................... ¶932
Sampling of Perishable Goods ...................................................................... ¶933
Reimportation and Import-for-Export .............................................................. ¶934
Special Procedures for Problem Importers ................................................ ¶935
Schematic Diagram of FDA’s Import Procedures ................................................ ¶936
Exportation ............................................................................................... ¶940
Exports of Unapproved Products .................................................................... ¶941
Exports of Investigational and Unfinished Products .............................................. ¶942
Labeling of Exports .................................................................................... ¶943
Export of Condemned Articles ........................................................................ ¶944
Export Certificates ...................................................................................... ¶945
Volume Two
Tab 1000: Civil Money Penalties
Executive Summary ................................................................................... ¶1000
Penalties Involving Medical Devices .......................................................... ¶1010
Penalties Involving Radiation-emitting Products ................................................ ¶1020
Penalties Involving Prescription Drugs ........................................................ ¶1030
Penalties Involving Biological and Other Public Health Products ......................... ¶1040
Penalties Involving Food ............................................................................. ¶1050
Penalties Involving Clinical Trial Registry and Results Data Bank Requirements .......... ¶1060
Penalties Involving Tobacco Products .......................................................... ¶1065
How FDA Imposes Civil Money Penalties .................................................... ¶1070
Initiation of Civil Money Penalty Proceedings .................................................. ¶1071
Evidence and Subpoena Authority .................................................................. ¶1072
Hearing Procedures .................................................................................... ¶1073
Appeals ........................................................................................................ ¶1074
Relationship Between Civil Money Penalties and Criminal Penalties: The Halper Case ................................... ¶1080
Tab 1100: Seizures
Executive Summary ................................................................................... ¶1100
Avoiding Seizure ....................................................................................... ¶1110
State Embargoes ....................................................................................... ¶1111
Medical Devices ....................................................................................... ¶1112
Counterfeit Drugs ..................................................................................... ¶1113
Foods .......................................................................................................... ¶1114
Tobacco Products ..................................................................................... ¶1115
The Seizure Process .................................................................................... ¶1120
Judicial Procedure ....................................................................................... ¶1121
Simple Seizures .......................................................................................... ¶1122
Mass Seizures ............................................................................................ ¶1123
Test Case Seizures ...................................................................................... ¶1124
Court Decisions on Seizures .......................................................................... ¶1125
How a Seizure Begins .................................................................................. ¶1130
How Products Are Seized ............................................................................ ¶1140
Claiming Seized Products ............................................................................ ¶1150
Challenging a Seizure .................................................................................. ¶1151
Disposition of Seized Products ...................................................................... ¶1160
Contesting FDA Seizures .............................................................................. ¶1161
Default and Destruction .............................................................................. ¶1162
Consent and Destruction .............................................................................. ¶1163
Tab 1200: Injunctions

Executive Summary ......................................................... ¶1200
Purpose of Injunctions .................................................... ¶1201
Injunction Trends ......................................................... ¶1202

Actions that Prompt FDA To Seek Injunctions ......................... ¶1210
Kinds of Injunctions ....................................................... ¶1220
Permanent Injunctions ................................................... ¶1221
Preliminary Injunction ................................................... ¶1222
Temporary Restraining Orders ........................................... ¶1223
Contempt ........................................................................ ¶1224

Procedures for Processing Injunctions ................................... ¶1230
FDA District Office Decisions About Injunctions ....................... ¶1231
Headquarters’ Decisions About Injunctions .............................. ¶1232
Review of Injunctions by FDA’s Office of General Counsel .......... ¶1233
Avoiding FDA Injunctions ................................................ ¶1240
Legal Standards of FDA Injunctions ..................................... ¶1250
Irreparable Harm ............................................................ ¶1251
Likelihood of Recurrence ................................................ ¶1252
Who May Be Enjoined ..................................................... ¶1253
Defenses Against Injunctions .............................................. ¶1260
Terms of Settlement for Injunctions ..................................... ¶1270
Typical Consent Decree ................................................... ¶1271
New “Standard” Terms of Injunctions ................................... ¶1272

Tab 1300: Criminal Liability

Executive Summary ......................................................... ¶1300
Who Files Charges? ........................................................ ¶1301
Availability of Defenses ................................................... ¶1302

Statutory Authority for Criminal Enforcement .......................... ¶1310
Acts That Are Misdemeanors ............................................. ¶1311
Acts That Are Felonies ..................................................... ¶1312

Strict Individual Liability:
The Park Doctrine ........................................................... ¶1320
The Dotterweich Case ...................................................... ¶1321
The Park Case ............................................................... ¶1322
Potential Conflicts of Interest .............................................. ¶1323

Vicarious Corporate Liability ................................................ ¶1330
Defenses ........................................................................ ¶1340
Objective Impossibility ..................................................... ¶1341
Responsible Relationship .................................................. ¶1342
Guaranty ......................................................................... ¶1343

When Will the FDA Recommend Prosecution? ......................... ¶1350
When Will the Justice Department Proceed? .......................... ¶1351

Opportunity to Present Views ............................................. ¶1360
When No 305 Meeting Is Offered ......................................... ¶1361
When a 305 Meeting Is Offered .......................................... ¶1362
Responding to a Notice for a 305 Meeting ............................. ¶1363
The 305 Meeting ............................................................ ¶1364

Violations With Knowledge or Intent ..................................... ¶1370
Federal Crimes Involving the FDA ....................................... ¶1380
Counterfeiting ............................................................... ¶1381

Tab 1400: Criminal Case Development

Executive Summary ......................................................... ¶1400
How the FDA Investigates Criminal Cases ............................ ¶1410
Investigation Coordination ................................................ ¶1411
Information Sought During Criminal Investigations ................. ¶1412
Documents Sought in Criminal Investigations ......................... ¶1413
Investigating Responsibility and Intent ................................ ¶1414
The Office of Criminal Investigations (OCI) .......................... ¶1415

How the FDA Processes Criminal Cases .............................. ¶1420
Prosecution Process When There Is a Section 305 Notice .......... ¶1421
Prosecution Process Without a Section 305 Notice .................... ¶1422
FDA Referrals for Criminal Investigation .............................. ¶1423
Contempt of Court and Violations of Probation ....................... ¶1424

Role of the Department of Justice ...................................... ¶1430
How the Department of Justice Processes FDA Referrals ............ ¶1431
Furthering the Investigation ............................................... ¶1432
The Grand Jury .................................................................. ¶1433
Search Warrants .................................................................. ¶1434
Resolution of the Investigation .......................................... ¶1435

Roles of Other Federal Organizations in FDA Investigations ....... ¶1440

Tab 1500: Sentencing

Executive Summary ......................................................... ¶1500
Importance of Corporate Compliance and Ethics Programs .......... ¶1501

Federal Sentencing Laws ................................................... ¶1510
Fines .............................................................................. ¶1511
Restitution ....................................................................... ¶1512
Forfeiture ........................................................................ ¶1513
Probation ......................................................................... ¶1514
Imprisonment................................................................. ¶1515
Statutory Criteria for Sentencing ......................................... ¶1516

The Sentencing Guidelines ................................................ ¶1520
Sentencing for Violations of the Federal Food, Drug and Cosmetic Act ........................................... ¶1521

Sentencing Individuals Under the Guidelines ........................ ¶1530
The Total Offense Level .................................................... ¶1531
How Prison Terms Are Calculated ....................................... ¶1532
Tab 1500 (cont’d)

How Individuals’ Fines Are Calculated ................................................. ¶1533
Departures That Affect Calculations ................................................. ¶1534

Sentencing Organizations Under the Guidelines ................................................. ¶1540
Restitution by Corporations ................................................. ¶1541
Fines for Corporations ................................................. ¶1542
Probation for Corporations ................................................. ¶1543
Guidelines Application to FDA-regulated Companies ............................................. ¶1544
Effective Compliance and Ethics Programs ................................................. ¶1545
Reporting Crimes ................................................. ¶1546
Ultimate Benefits of Compliance and Ethics Programs ................................................. ¶1547
Office of Inspector General Voluntary Compliance Guidance for Pharmaceutical Companies ................................................. ¶1548

Tab 1600: Current Good Manufacturing Practices ................................................. ¶1600

The Basis of Current Good Manufacturing Practice ................................................. ¶1610

The Regulation of CGMPs ................................................. ¶1620
CGMP Requirements ................................................. ¶1621
CGMP Guidance ................................................. ¶1622
Judicial Enforcement ................................................. ¶1623
Warning Letters ................................................. ¶1624
Delay in Product Approval ................................................. ¶1625
Other Consequences of CGMP Noncompliance ................................................. ¶1626
Costs of Compliance ................................................. ¶1627

The Drug CGMPs ................................................. ¶1630
Scope and Application ................................................. ¶1631
Requirements ................................................. ¶1632
Revisions to the Drug CGMP ................................................. ¶1633

The Device Quality System Regulations ................................................. ¶1640
Scope and Application ................................................. ¶1641
Requirements ................................................. ¶1642
Compliance Issues ................................................. ¶1643

The Food Sanitation Regulations ................................................. ¶1650
Requirements ................................................. ¶1651
HACCP ................................................. ¶1652
Dietary Supplements ................................................. ¶1653
Other Food Processing CGMP Regulations ................................................. ¶1654

Other FDA CGMP Requirements ................................................. ¶1660
Biological Products ................................................. ¶1661
Medicated Animal Feeds ................................................. ¶1662
Cosmetics ................................................. ¶1663
Tobacco Products ................................................. ¶1664
Combination Products ................................................. ¶1665

CGMP Inspections ................................................. ¶1670
FDA Inspection Authority ................................................. ¶1671
CGMP Inspection Issues ................................................. ¶1672
Responding to a CGMP Inspection ................................................. ¶1673
How FDA Assesses CGMP Noncompliance ................................................. ¶1674


Appendix I

U.S. Criminal Code
Selected Sections
False, Fictitious or Fraudulent Claims ................................................. §287
Conspiracy to Commit Offense or to Defraud United States ................................................. §371
Power of Court ................................................. §401
Smuggling Goods into the United States ................................................. §545
Statements or Entries Generally ................................................. §1001
Frauds and Swindles ................................................. §1341
Fraud by Wire, Radio, or Television ................................................. §1343
Injunctions against Fraud ................................................. §1345
Tampering with Consumer Products ................................................. §1365
Influencing or Injuring Officer or Juror Generally ................................................. §1503
Obstruction of Proceeding before Departments, Agencies, and Committees ................................................. §1505
Prohibited Activities ................................................. §1962
Imposition of a Sentence ................................................. §3553
Sentence of Fine ................................................. §3571
Imposition of a Sentence of Fine and Related Matters ................................................. §3572

Federal Food, Drug and Cosmetic Act, as Amended (21 U.S.C. §301 et seq.)
Selected Sections
Chapter II — Definitions
Definitions; Generally ................................................. Sec. 201

Chapter III — Prohibited Acts
Prohibited Acts ................................................. Sec. 301
Injunction Proceedings ................................................. Sec. 302
Penalties ................................................. Sec. 303
Seizure ................................................. Sec. 304
Hearing Before Report of Criminal Violation ................................................. Sec. 305
Debarment, Temporary Denial of Approval, and Suspension ................................................. Sec. 306
Civil Penalties ................................................. Sec. 307
Authority to Withdraw Approval of Abbreviated Drug Applications ................................................. Sec. 308
Report of Minor Violations ................................................. Sec. 309
Proceedings in Name of United States; Provision as to Subpoenas ................................................. Sec. 310

Chapter IV — Food
Adulterated Food ................................................. Sec. 402
Misbranded Food ................................................. Sec. 403
National Uniform Nutrition Labeling ................................................. Sec. 403A

Chapter V — Drugs and Devices
Adulterated Drugs and Devices ................................................. Sec. 501
Misbranded Drugs and Devices ................................................. Sec. 502
Notification and Other Remedies ................................................. Sec. 518
State and Local Requirements Respecting Devices ................................................. Sec. 521
Definitions ................................................. Sec. 531
Notification of Defects in, and Repair or Replacement of, Electronic Products ................................................. Sec. 535

© Thompson Publishing Group April 2015

Table of Contents • Page 9
Chapter VI — Cosmetics
Adulterated Cosmetics [§361]........................................Sec. 601
Mislabeled Cosmetics [§362]........................................Sec. 602

Chapter VII — General Administrative Provisions
Regulations and Hearings [§371]..............................Sec. 701
Examinations and Investigations [§372]...............Sec. 702
Records of Interstate Shipment [§373]..............Sec. 703
Factory Inspection [§374]....................................Sec. 704
Publicity [§375]........................................Sec. 705
Seafood Inspection...........................................Sec. 706
Presumption of Existence of Jurisdiction [§379a]..........................Sec. 709

Chapter VIII — Imports and Exports
Imports and Exports [§381]..........................Sec. 801
Exports of Certain Unapproved Products [§382]........Sec. 802

Biologics Control Act, as Amended
Selected Sections
Regulation of Biological Products ..................§262

Federal Rules of Civil Procedure
Selected Rules
Injunctions..............................................Rule 65

Supplemental Rules to Federal Rules of Civil Procedure
Selected Rules
Actions In Rem: Special Provisions.................Rule C
Actions In Rem and Quasi In Rem: General Provisions.................................................Rule E

Federal Rules of Criminal Procedure
Selected Rules
The Grand Jury........................................Rule 6
Search and Seizure....................................Rule 41

Sentencing Guidelines
Selected Guidelines
Chapter 2 — Offense Conduct
Part B — Basic Economic Offenses
1. Theft, Embezzlement, Receipt of Stolen Property, Property Destruction, and Offenses Involving Fraud or Deceit
Larceny, Embezzlement, and Other
Forms of Theft; Offenses Involving Stolen Property; Property Damage or Destruction; Fraud and Deceit; Forgery; Offenses Involving Altered or Counterfeit Instruments Other than Counterfeit Bearer Obligations of the United States ..................§2B1.1

2. Food, Drugs, Agricultural Products, and Consumer Products
Violations of Statutes and Regulations Dealing With Any Food, Drug, Biological Product, Device, Cosmetic, Agricultural Product, or Consumer Product ...........................................§2N1.1

Chapter 8 — Sentencing of Organizations
Part A — General Application Principles
Applicability of Chapter Eight ......................§8A1.1
Application Instructions — Organizations ....§8A1.2

Part B — Remedying Harm From Criminal Conduct, and Effective Compliance and Ethics Program
1. Remedying Harm From Criminal Conduct
Restitution — Organizations .......................§8B1.1
Remedial Orders — Organizations
(Policy Statement)........................................§8B1.2
Community Service — Organizations
(Policy Statement)........................................§8B1.3
Order of Notice to Victims — Organizations ...§8B1.4

2. Effective Compliance and Ethics Program
Effective Compliance and Ethics Program ....§8B2.1

Part C — Fines
1. Determining the Fine — Criminal Purpose Organizations
Determining the Fine — Criminal Purpose Organizations ...........................................§8C1.1

2. Determining the Fine — Other Organizations
Applicability of Fine Guidelines ..................§8C2.1
Preliminary Determination of Inability to Pay Fine ...........................................§8C2.2
Offense Level...........................................§8C2.3
Base Fine...............................................§8C2.4
Culpability Score......................................§8C2.5
Minimum and Maximum Multipliers ........§8C2.6
Guideline Fine Range — Organizations ....§8C2.7
Determining the Fine Within the Range
(Policy Statement)........................................§8C2.8
Disgorgement...........................................§8C2.9
Determining the Fine for Other Counts ....§8C2.10

3. Implementing the Sentence of a Fine
Imposing a Fine...........................................§8C3.1
Payment of the Fine — Organizations ....§8C3.2
Reduction of Fine Based on Inability to Pay....§8C3.3
Fines Paid by Owners of Closely Held Organizations ...........................................§8C3.4

4. Departures From the Guideline Fine Range
Substantial Assistance to Authorities — Organizations(Policy Statement) ....§8C4.1
Risk of Death or Bodily Injury (Policy Statement) ...........................................§8C4.2
### Appendix I (cont’d)

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Threat to National Security (Policy Statement)</td>
<td>§8C4.3</td>
</tr>
<tr>
<td>Threat to the Environment (Policy Statement)</td>
<td>§8C4.4</td>
</tr>
<tr>
<td>Threat to a Market (Policy Statement)</td>
<td>§8C4.5</td>
</tr>
<tr>
<td>Official Corruption (Policy Statement)</td>
<td>§8C4.6</td>
</tr>
<tr>
<td>Public Entity (Policy Statement)</td>
<td>§8C4.7</td>
</tr>
<tr>
<td>Members or Beneficiaries of the Organization as Victims (Policy Statement)</td>
<td>§8C4.8</td>
</tr>
<tr>
<td>Remedial Costs that Greatly Exceed Gain (Policy Statement)</td>
<td>§8C4.9</td>
</tr>
<tr>
<td>Mandatory Programs to Prevent and Detect Violations of Law (Policy Statement)</td>
<td>§8C4.10</td>
</tr>
<tr>
<td>Exceptional Organizational Culpability (Policy Statement)</td>
<td>§8C4.11</td>
</tr>
<tr>
<td><strong>Part D – Organizational Probation</strong></td>
<td></td>
</tr>
<tr>
<td>Imposition of Probation – Organizations</td>
<td>§8D1.1</td>
</tr>
<tr>
<td>Term of Probation – Organizations</td>
<td>§8D1.2</td>
</tr>
<tr>
<td>Conditions of Probation – Organizations</td>
<td>§8D1.3</td>
</tr>
<tr>
<td>Recommended Conditions of Probation – Organizations (Policy Statement)</td>
<td>§8D1.4</td>
</tr>
<tr>
<td>[Deleted]</td>
<td>§8D1.5</td>
</tr>
<tr>
<td><strong>Part E – Special Assessments, Forfeitures, and Costs</strong></td>
<td></td>
</tr>
<tr>
<td>Special Assessments – Organizations</td>
<td>§8E1.1</td>
</tr>
<tr>
<td>Forfeiture – Organizations</td>
<td>§8E1.2</td>
</tr>
<tr>
<td>Assessment of Costs – Organizations</td>
<td>§8E1.3</td>
</tr>
<tr>
<td><strong>Part F – Violations of Probation – Organizations</strong></td>
<td></td>
</tr>
<tr>
<td>Violations of Conditions of Probation – Organizations (Policy Statement)</td>
<td>§8F1.1</td>
</tr>
</tbody>
</table>

### Title 21 Code of Federal Regulations

#### Part 1 – General Enforcement Regulations

##### Subpart E – Imports and Exports

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definitions</td>
<td>§1.83</td>
</tr>
<tr>
<td>Notice of Sampling</td>
<td>§1.90</td>
</tr>
<tr>
<td>Payment for Samples</td>
<td>§1.91</td>
</tr>
<tr>
<td>Hearing on Refusal of Admission</td>
<td>§1.94</td>
</tr>
<tr>
<td>Application for Authorization to Relabel and Recondition</td>
<td>§1.95</td>
</tr>
<tr>
<td>Granting of Authorization to Relabel and Recondition</td>
<td>§1.96</td>
</tr>
<tr>
<td>Bonds</td>
<td>§1.97</td>
</tr>
<tr>
<td>Costs Chargeable in Connection with Relabeling and Reconditioning</td>
<td></td>
</tr>
<tr>
<td>Inadmissible Imports</td>
<td>§1.99</td>
</tr>
</tbody>
</table>

##### Subpart F – Violations of Probation – Organizations

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Examination and Investigation Samples</td>
<td>§2.10</td>
</tr>
</tbody>
</table>

##### Subpart B – Initiation of Proceedings

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Method of Analysis</td>
<td>§2.19</td>
</tr>
</tbody>
</table>

##### Subpart A – General Provisions

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definitions</td>
<td>§7.3</td>
</tr>
<tr>
<td>Suggested Forms of Guaranty</td>
<td>§7.13</td>
</tr>
</tbody>
</table>

### Appendix II

**Subpart C – Recalls (Including Product Corrections)**

- Guidelines on Policy, Procedures, and Industry Responsibilities
  - Recall Policy                                                        | §7.40 |
  - Health Hazard Evaluation and Recall                                  | §7.41 |
  - Recall Strategy                                                      | §7.42 |
  - Food and Drug Administration-requested Recall                        | §7.45 |
  - Firm-initiated Recall                                                | §7.46 |
  - Recall Communications                                                | §7.49 |
  - Public Notification of Recall                                        | §7.50 |
  - Recall Status Reports                                                | §7.53 |
  - Termination of a Recall                                              | §7.55 |
  - General Industry Guidance                                            | §7.59 |

**Subpart E – Criminal Violations**

- Opportunity for Presentation of Views before Report of Criminal Violation | §7.84 |
- Conduct of a Presentation of Views before Report of Criminal Violation  | §7.85 |
- Records Related to Opportunities for Presentation of Views Conducted before Report of Criminal Violation | §7.87 |

### Part 10 – Administrative Practices and Procedures

#### Subpart B – General Administrative Procedures

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Citizen Petition</td>
<td>§10.30</td>
</tr>
<tr>
<td>Administrative Reconsideration of Action</td>
<td>§10.33</td>
</tr>
<tr>
<td>Documentation of Significant Decisions in Administrative File</td>
<td>§10.70</td>
</tr>
<tr>
<td>Internal Agency Review of Decisions</td>
<td>§10.75</td>
</tr>
<tr>
<td>Advisory Opinions</td>
<td>§10.85</td>
</tr>
<tr>
<td>Food and Drug Administration Regulations, Guidelines, Recommendations, and Agreements</td>
<td>§10.90</td>
</tr>
</tbody>
</table>

#### Subpart A – General Provisions

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scope</td>
<td>§12.1</td>
</tr>
</tbody>
</table>

**Subpart B – Initiation of Proceedings**

- Initiation of a Hearing Involving the Issuance, Amendment, or Revocation of a Regulation | §12.20 |

#### Part 16 – Regulatory Hearing before the Food and Drug Administration

##### Subpart A – General Provisions

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scope</td>
<td>§16.1</td>
</tr>
</tbody>
</table>

##### Part 17 – Civil Money Penalties Hearings

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scope</td>
<td>§17.1</td>
</tr>
<tr>
<td>Maximum penalty amounts</td>
<td>§17.2</td>
</tr>
<tr>
<td>Definitions</td>
<td>§17.3</td>
</tr>
<tr>
<td>Complaint</td>
<td>§17.5</td>
</tr>
<tr>
<td>Service of complaint</td>
<td>§17.7</td>
</tr>
<tr>
<td>Answer</td>
<td>§17.9</td>
</tr>
<tr>
<td>Default upon failure to file an answer</td>
<td>§17.11</td>
</tr>
<tr>
<td>Notice of hearing</td>
<td>§17.13</td>
</tr>
<tr>
<td>Parties to the hearing</td>
<td>§17.15</td>
</tr>
<tr>
<td>Summary decisions</td>
<td>§17.17</td>
</tr>
<tr>
<td>Interlocutory appeal from ruling of presiding officer</td>
<td>§17.18</td>
</tr>
</tbody>
</table>
Appendix II (cont’d)
Authority of the presiding officer ..................................................... §17.19
Ex parte contacts ........................................................................... §17.20
Prehearing conferences ................................................................. §17.21
Discovery ...................................................................................... §17.22
Exchange of witness lists, witness statements, and exhibits ........... §17.23
Hearing subpoenas ......................................................................... §17.25
Protective order ............................................................................. §17.26
Fees ............................................................................................... §17.27
Computation of time ...................................................................... §17.29
Form, filing, and service of papers .................................................. §17.31
Motions .......................................................................................... §17.32
The hearing and burden of proof ................................................... §17.33
Determining the amount of penalties and assessments ..................... §17.34
Sanctions ....................................................................................... §17.35
Witnesses ...................................................................................... §17.36
Evidence ....................................................................................... §17.37
The administrative record ............................................................... §17.38
Posthearing briefs .......................................................................... §17.41
Initial decision .............................................................................. §17.42
Appeals .......................................................................................... §17.43
Harmless error .............................................................................. §17.44
Judicial review ............................................................................. §17.45
Deposit in the Treasury of the United States ................................... §17.51

Title 45 Code of Federal Regulations
Subtitle A
Part 17 - Release of Adverse Information to News Media
Definition ..................................................................................... §17.1
Basic Policy .................................................................................... §17.2
Precautions to be Taken ................................................................. §17.3
Regulatory Investigations and Trial-type Proceedings ..................... §17.4
Context to be Reflected ................................................................... §17.5
Advance Notice ............................................................................ §17.6
Retractions or Corrections .............................................................. §17.7

Appendix III
United States v. Park, 421 U.S. 658 (1975)
United States v. Jamieson-McKames Pharmaceuticals Inc., 651 F.2d 532 (8th Cir. 1981)
United States v. Gel Spice Co., 773 F.2d 427 (2d Cir. 1985)
United States v. Odessa Union Warehouse Co-op, 833 F.2d 172 (9th Cir. 1987)
United States v. Universal Management Services Inc., 191 F.3d 750 (6th Cir. 1999)
United States v. Lane Labs-USA Inc., 427 F.3d 219 (3d Cir. 2005)

Appendix IV
Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities; Final Policy
Points to Consider for Internal Reviews and Corrective Action Operating Plans
Government-wide Quality Assurance Program Manual
Administrative Practices and Procedures; Advisory Opinions and Guidelines; Proposed Rule
Good Guidance Practices
Product Recalls, Including Removals and Corrections
Guidance for Records Access Authority Provided in Title III, Subtitle A, of the Public Health Security and Bioterrorism Preparedness and Response Act of 2002
Using Electronic Means to Distribute Certain Product Information
Marketed Unapproved Drugs – Compliance Policy Guide
Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products (excerpts) (FDA statement on preemption of state law by agency approval of labeling)
Supplemental Applications Proposing Labeling Changes for Approved Drugs, Biologics, and Medical Devices
Enforcement Policy Concerning Certain Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco
Enforcement Policy Concerning Rotational Warning Plans for Smokeless Tobacco Products
Food and Drug Administration Enforcement Strategy (July 15, 2010)
Enforcement Action Plan for Promotion and Advertising Restrictions (Center for Tobacco Products)
Civil Money Penalties and No-Tobacco-Sale Orders for Tobacco Retailers

Appendix V
Form 463a (Affidavit)
Form 482 (Notice of Inspection)
Form 482a (Demand for Records)
Form 482b (Request for Information)
Form 482c (Notice of Inspection – Request for Records)
Form 483 (Inspectional Observations)
Form 484 (Receipt for Samples)
Notice of FDA Action
Resources for FDA Regulated Businesses

Glossary [RESERVED]

Index
Subject Index
Case Index

[The next page is Current Contents, Page 31.]